Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E.
Target Price
The average target price of ACE.ST is 6.5 and suggests 114% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell